Mezzion Pharma Co.Ltd (140410.KQ) stock: key figures, P/E, revenue and dividend
Health Care · Pharmaceuticals · South Korea · ISIN KR7140410002
Mezzion Pharma Co.Ltd financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 8.61 bn KRW | 7.91 bn KRW |
| Gross profit | 1.91 bn KRW | 1.45 bn KRW |
| Operating income | -14.30 bn KRW | -16.77 bn KRW |
| EBIT | -14.23 bn KRW | -37.27 bn KRW |
| Net income | -19.48 bn KRW | -34.93 bn KRW |
| Diluted EPS – continuing operations | -650.02 KRW | -1,149.27 KRW |
Full history since 2012, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Mezzion Pharma Co.Ltd
Mezzion Pharma Co.,Ltd. engages in the development, licensing, and commercialization of drugs for the treatment of vascular diseases. It is developing Udenafil, a PDE5 inhibitor to treat erectile dysfunction, benign prostatic hyperplasia, pulmonary arterial hypertension, overactive bladder, hepatic portal hypertension, and chronic obstructive pulmonary diseases. The company was formerly known as Dong-A Pharmtech Co., Ltd. and changed its name to Mezzion Pharma Co.,Ltd. in April 2013. Mezzion Pharma Co.,Ltd. was founded in 2002 and is based in Seoul, South Korea.
More stocks
- Jiangsu Bide Science and Technology Co. Ltd. (605298.SS)
- MBB (MBB.DE)
- GVS SpA (GVS.MI)
- EFORT Intelligent Equipment Co Ltd (688165.SS)
- Naturenergie Holding AG (NEAG.SW)
- Orezone Gold Corp (ORE.TO)
- Guangdong Anda Automation Solutions Co. Ltd. A (688125.SS)
- Taiwan Hon Chuan Enterprise Co Ltd (9939.TW)
- Vivenio Residencial SOCIMI SA (YVIV.MC)
- Creades publ AB (CRED A.ST)
- ITMAX System Berhad (5309.KL)
- Everest Medicines Ltd (1952.HK)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.